Kontafarma China Holdings Limited (HKG:1312)

Market Cap	156.48M
Revenue (ttm)	914.71M +1.9%
Net Income	-427.85M
EPS	-0.08
Shares Out	5.59B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,354,000
Average Volume	1,087,350
Open	0.0290
Previous Close	0.0300
Day's Range	0.0270 - 0.0290
52-Week Range	0.0220 - 0.0480
Beta	0.02
RSI	42.22
Earnings Date	Mar 27, 2026

About Kontafarma China Holdings

Kontafarma China Holdings Limited, an investment holding company, manufactures and sells chemical drugs, active pharmaceutical ingredients (API), and API intermediate in Mainland China, Singapore, Taiwan, and internationally. It operates through Pharmaceutical Business and Fitness Business segments. The company offers prescription drugs, including chemical drugs and prescribed traditional Chinese medicines; operates fitness and yoga centers, as well as franchise business; and provides management and consultation services for fitness and health ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2011
• Employees: 636
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1312

Financial Performance

In 2025, Kontafarma China Holdings's revenue was 914.71 million, an increase of 1.92% compared to the previous year's 897.52 million. Losses were -427.85 million, 466.4% more than in 2024.